Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: A randomized trial

AIDS

Volumn 13, Issue 1, 1999, Pages

  Kirk, Ole ^a   Katzenstein, Terese L ^a   Gerstoft, Jan ^a   Mathiesen, Lars ^a   Nielsen, Henrik ^b   Pedersen, Court ^c   Lundgren, Jens D ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

^c NONE

Author keywords

Efficacy; Indinavir; Randomized controlled trial; Ritonavir; Safety; Saquinavir

Indexed keywords

INDINAVIR; NUCLEOSIDE ANALOG; RITONAVIR; SAQUINAVIR; VIRUS RNA;

ADULT; ARTICLE; BLOOD TOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; NEUROTOXICITY; PANCREAS DISEASE; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADULT; ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; MALE; MIDDLE AGED; RITONAVIR; SAQUINAVIR; TIME FACTORS;

EID: 0032988176     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199901140-00002     Document Type: Article

References (20)

1. 1. Carpenter CCJ, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society - USA Panel. JAMA 1998, 280:78-86.
2. 2. Gazzard B, Moyle G: 1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals, Lancet 1998, 352:314-316.
3. 3. Kirk O, Mocroft A, Katzenstein TL, et al., for the EuroSIDA study group: Changes in use of antiretroviral therapy in regions of Europe over time. AIDS 1998, 12:2031-2039.
4. 4. Cameron DW, Heath-Chiossi M, Danner S, et al., for the Advanced HIV Disease Ritonavir Study Group: Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet 1998, 351:543-549.
5. 5. Hammer SM, Squires KE, Hughes MD, et al., for the AIDS Group 320 Study Team: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 336:725-73.
6. 6. Gulick RM, Mellors JVV, Havlir D, et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
7. 7. Paella FJ Jr, Delaney KM, Moorman AC, et al., and the HIV Outpatient Study Investigators: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998, 338:853-860.
8. 8. Mouton Y, Alfandari S, Valette M, et al., and the Fédération Nationale des Centres de Lutte contre le SIDA: Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. AIDS 1997, 11:F101-F105.
9. 9. Egger M, Hirschel B, Francioli P, et al., and the Swiss HIV Cohort Study: Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. BMJ 1997, 315:1194-1199.
10. 10. Mocroft A, Vella S, Benfield T, et al., for the EuroSIDA study group Changing patterns of mortality in patients infected with HIV. Lancet 1998, 352:1725-1730.
11. 11. Fätkenheuer G, Theisen A, Rockstroh J, et al.: Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients AIDS 1997, 11:F113-F116.
12. 12. Cohen C, Sun E, Cameron W, et al.: Ritonavir-saquinavir combination therapy in HIV-infected patients. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans. September 1996 [abstract LB7b].
13. 13. Hsu A, Granneman GR, Cao G, et al: Pharmacokinetic interactions between two immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther 1998, 63:453-464.
14. 14. Merry C, Barry MG, Mulcahy F, et al.: Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 1997, 11:F29-F33.
15. 15. Hsu A, Vasavanonda S, Chernyavskiy, et al.: Modelling the in vivo potency of ritonavir-based dual protease inhibitor regimens. 2nd International Workshop on HIV Drug Resistance and Treatment Strategies. Lake Maggiore, Italy. June 1998 [abstract 73].
16. 16. Decks SG, Grant RM, Beatty GW, Horton C, Detmer J, Eastman S. Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure. AIDS 1998, 12:F97-F102.
17. 17. Rhone SA, Hogg RS, Yip B, et al.: The antiviral effect of ritonavir and saquinavir in combination amongst HIV-infected adults: results from a community-based study AIDS 1998, 12:619-624.
18. 18. Centers for Disease Control and Prevention: 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992, 41:1-19.
19. 19. Hill A, Demasi R, Kuhn M, and Avanti Steering Committee: Different analyses give highly variable estimates of HIV-1 RNA undetectability and log reduction in clinical trials. 12th World AIDS Conference. Geneva. June - July 1998 [abstract 42204].
20. 20. Kempf DJ, Rode RA, Xu Y, et al.: The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir AIDS 1998, 12:F9-F14.